Clinical Trial

Testing Experimental Treatment for Frontotemporal Dementia

Study Description

A Study to Evaluate Safety of Long-term AL001 Dosing in FTD Patients

A Phase 2 open label study evaluating the safety, tolerability, PK and PD of AL001 in participants with a Granulin mutation or C9orf72 mutation causative of frontotemporal dementia.

Location

Locations Selected Location

Methods

Pharmaceutical medication involved Pharmaceutical medication involved
Recruiting patients only Recruiting patients only

Drug - AL001

administered via intravenous (IV) infusion once a month

Additional Information

Official Study Title

A Phase 2, Multicenter, Open-Label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AL001 in Heterozygous Carriers of Granulin or C9ORF72 Mutations Causative of Frontotemporal Dementia

Clinical Trial ID

NCT03987295

ParticipAid ID

bYE92b